Home >> Research And Markets : Between 2006 And 2010 There Could Be Six New Drug Launches In The Endometriosis Market

Research and Markets : Between 2006 and 2010 There Could Be Six New Drug Launches in the Endometriosis Market

Research and Markets (researchandmarkets.com/reports/c15338) has announced the addition of Endometriosis Pipeline Forecast to their offering. Dublin (PRWEB) April 11, 2005 -- Research and Markets http://www.researchandmarkets.com/reports/c15338) has announced the addition of Endometriosis Pipeline Forecast to their offering. Endometriosis is treated with a number of drug classes, including hormonal contraceptives, progestogens and GnRH agonists, which are also used in other indications. This endometriosis forecast incorporates IMS diagnosis and MIDAS sales data into our in-house forecasting model to give a disease specific forecast that sees market growth from $1.31 billion in 2003 to $1.85 billion by 2014. Scope of this report Between 2006 and 2010 there could be six new drug launches in the endometriosis market, providing the impetus behind growth in the area and to some extent off-setting the impact of major GnRH agonist patent expiries. Key novel drugs include Schering AG’s Endometrion and asoprisnil, developed with TAP Pharmaceuticals. Disease specific forecasting by major geographical market, allows for a snapshot of regional prescribing practices and comparison between countries. It highlights key differences between these markets, such as the use of higher value products or reliance on older therapies, as well as the varying position of competitors within a therapeutic class. This report offers -Reacting to the latest news breaking in your industry -Forecasts of pipeline and marketed product sales in endometriosis from 2004-2014, using Datamonitor’s proprietary forecasting methodology -Historical IMS MIDAS sales data across the seven major pharmaceutical markets: US, Japan, France, Germany, Italy, Spain and the UK -Includes application of IMS sales by endometriosis diagnosis codes in key IMS ATC classes: G3A, G3D, G3H, H1C3 and GnRH agonists Reasons to Purchase -Support your commercial planning on accurate, endometriosis-specific market data by excluding product sales for indications other than endometriosis -Identify key competitors in local markets and target those with the potential for investment and development -Evaluate the potential of new drugs in development and in impact of key patent expiries on the market For more information visit http://www.researchandmarkets.com/reports/c15338 Laura Wood Senior Manager Research and Markets e-mail protected from spam bots Fax: +353 1 4100 980